{{ window.visitor.corporateClient.name }}

Företagslösning

{{ window.visitor.ipAccess.corporateClient.name }}

{{ window.visitor.corporateClient.name }}
Välkommen till vår företagslösning

Här kan du administrera användarna i din företagslösning.
Välkommen till din prenumeration för Life Science Sweden.
Welcome to our Corporate client solution

Your IP is registered with the company mentioned above and provides access to Life Science Sweden.

Click here to go to sign-up

Annons

Innehållet nedan modereras inte i förväg och omfattas därmed inte av webbplatsens utgivningsbevis.

Dela sida

Sponsrat innehåll

ZEISS and EDGE leverage AI to transform bioimaging in the biopharma industry

Transforming complex bioimaging data to workflows offering actionable insights for decision-making to speed up drug discovery.

Through their collaboration, ZEISS and EDGE Biotechnologies aim to pioneer advanced biopharma solutions and reshape the role of bioimaging from a “niche tool” to a “core quantitative decision-making engine” in the biopharma industry.

By combining the leadership of ZEISS in optical innovation with EDGE’s assays and AI analytics, the collaboration aspires to deliver end-to-end solutions to customers that simplify their workflows, enhance their research capabilities, and enable faster decisions – as well as complementing customers’ existing AI missions with novel data sets.

You can find further information here.